Aadi Bioscience, Inc. (AADI)
Largest Insider Buys in Sector
AADI Stock Price History Chart
AADI Stock Performance
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Insider Activity of Aadi Bioscience, Inc.
Over the last 12 months, insiders at Aadi Bioscience, Inc. have bought $0 and sold $685,452 worth of Aadi Bioscience, Inc. stock.
On average, over the past 5 years, insiders at Aadi Bioscience, Inc. have bought $23.4M and sold $767,930 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,529,402 shares for transaction amount of $20M was made by Dalal Anupam (director) on 2021‑08‑26.
List of Insider Buy and Sell Transactions, Aadi Bioscience, Inc.
| 2024-10-03 | Sale | CHIEF EXECUTIVE OFFICER | 9,689 0.04% | $1.94 | $18,797 | +12.50% | ||
| 2024-09-03 | Sale | EXECUTIVE CHAIRMAN | 40,000 0.1595% | $1.71 | $68,316 | +20.69% | ||
| 2024-08-05 | Sale | EXECUTIVE CHAIRMAN | 5,652 0.0224% | $1.34 | $7,595 | +44.20% | ||
| 2024-08-02 | Sale | EXECUTIVE CHAIRMAN | 18,933 0.0777% | $1.41 | $26,705 | +42.14% | ||
| 2024-08-01 | Sale | EXECUTIVE CHAIRMAN | 15,415 0.0618% | $1.50 | $23,055 | +29.93% | ||
| 2024-07-02 | Sale | EXECUTIVE CHAIRMAN | 8,652 0.0296% | $1.34 | $11,612 | 0.00% | ||
| 2024-07-01 | Sale | EXECUTIVE CHAIRMAN | 31,348 0.1161% | $1.45 | $45,605 | 0.00% | ||
| 2024-06-04 | Sale | EXECUTIVE CHAIRMAN | 20,225 0.0827% | $1.77 | $35,746 | +6.53% | ||
| 2024-06-03 | Sale | EXECUTIVE CHAIRMAN | 19,775 0.0805% | $1.81 | $35,765 | +3.31% | ||
| 2024-05-01 | Sale | EXECUTIVE CHAIRMAN | 40,000 0.162% | $1.93 | $77,184 | -3.61% | ||
| 2024-04-02 | Sale | EXECUTIVE CHAIRMAN | 22,228 0.0925% | $2.23 | $49,513 | -14.22% | ||
| 2024-04-01 | Sale | EXECUTIVE CHAIRMAN | 17,772 0.0725% | $2.31 | $41,101 | -19.05% | ||
| 2024-03-04 | Sale | EXECUTIVE CHAIRMAN | 14,964 0.0532% | $2.10 | $31,415 | -21.63% | ||
| 2024-03-01 | Sale | EXECUTIVE CHAIRMAN | 27,036 0.113% | $1.97 | $53,226 | -0.52% | ||
| 2024-02-01 | Sale | Executive Chairman | 42,000 0.1683% | $1.74 | $73,269 | +8.52% | ||
| 2024-01-02 | Sale | Executive Chairman | 42,000 0.1709% | $2.06 | $86,549 | -8.50% | ||
| 2023-12-06 | Sale | Executive Chairman | 7,037 0.0294% | $4.82 | $33,914 | -59.57% | ||
| 2023-12-05 | Sale | Executive Chairman | 15,740 0.0662% | $5.02 | $78,941 | -61.07% | ||
| 2023-12-04 | Sale | Executive Chairman | 10,876 0.0447% | $5.15 | $55,986 | -62.82% | ||
| 2023-12-01 | Sale | Executive Chairman | 8,347 0.035% | $5.14 | $42,881 | -61.92% |
Insider Historical Profitability
| Satter Muneer A | 5621835 22.809% | $3.39 | 33 | 0 | ||
| Khuong Chau Quang | 5193946 21.073% | $3.39 | 2 | 0 | ||
| Novartis Bioventures Ltd | 10 percent owner | 4049804 16.431% | $3.39 | 1 | 21 | |
| WEISS PAUL M | director | 1576167 6.3949% | $3.39 | 1 | 0 | |
| Dalal Anupam | director | 1529402 6.2051% | $3.39 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Avoro Capital Advisors Llc | $6.67M | 11.61 | 2.85M | 0% | +$0 | 0.08 | |
| ACUTA CAPITAL PARTNERS LLC | $4.33M | 7.53 | 1.85M | 0% | +$0 | 2.81 | |
| Alerce Investment Management L P | $3.82M | 6.64 | 1.63M | 0% | +$0 | 0.05 | |
| BlackRock | $2.44M | 4.24 | 1.04M | -3.76% | -$95,062.42 | <0.0001 | |
| The Vanguard Group | $2M | 3.49 | 856,836 | -0.33% | -$6,694.74 | <0.0001 |